ZINGO Drug Patent Profile
✉ Email this page to a colleague
When do Zingo patents expire, and what generic alternatives are available?
Zingo is a drug marketed by Powder Pharms and is included in one NDA. There are three patents protecting this drug.
This drug has seventeen patent family members in ten countries.
The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zingo
A generic version of ZINGO was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18th, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZINGO?
- What are the global sales for ZINGO?
- What is Average Wholesale Price for ZINGO?
Summary for ZINGO
| International Patents: | 17 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 141 |
| Patent Applications: | 3,384 |
| What excipients (inactive ingredients) are in ZINGO? | ZINGO excipients list |
| DailyMed Link: | ZINGO at DailyMed |
Pharmacology for ZINGO
| Drug Class | Amide Local Anesthetic Antiarrhythmic |
| Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for ZINGO
ZINGO is protected by three US patents.
Patents protecting ZINGO
Particle cassettes and processes therefor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
Particle cassettes and processes therefor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
Devices and methods for delivering particles
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZINGO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZINGO
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
